
 
 
 
 
 
 
 
 
   
 1. A compound of Formula I:      wherein, W1, W2 and W3 are each independently selected from   the chain from the tricycle terminates at W3, W2 or W1 with W3, W2 or W1 respectively being either -CH=O or -CH2OH;  R1 is selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, C3-10heterocycloalkyl, C(O)C1-10alkyl, C(O)C2-10alkenyl, C(O)C2-10alkynyl, C(O)C6-10aryl, C(O)C5-10heteroaryl, C(O)C3-10cycloalkyl;  C(O)C3-10heterocycloalkyl or a C-coupled amino acid; R2, R3, and R4 are each independently selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, C3-10heterocycloalkyl, C(O)H, C(O)C3-10alkyl, C(O)C2-10alkenyl, C(O)C2-10alkynyl, C(O)C6-10aryl, C(O)C5-10heteroaryl, C(O)C3-10cycloalkyl; C(O)C3-10heterocycloalkyl or a C-coupled amino acid;      R5 and R6 are each independently selected from H, OH and OC1-6alkyl; wherein, when any of R1, R2, R3, R4, R5 and R6 comprises an alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, then the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group is optionally substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, C1-6alkyl, C2-7alkenyl, C2-7alkynyl, C3-10cycloalkyl, C3-10heterocycloalkyl, C6-10aryl, C5-10heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino and formyl; and with the proviso that when W1, W2 and W3 are all -CH=C(CH3)-, and R2, R3 and R4 are all H, then R1 is not H; or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 2. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is H.  
 
     
 3. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is CH3.  
 
     
 4. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is C1-10alkyl.  
 
     
 5. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is C1-10 alkenyl.  
 
     
 6. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R2 is H.  
 
     
 7. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R3 is H.  
 
     
 8. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R4 is H.  
 
     
 9. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R2, R3 and R4 are each H.  
 
     
 10. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein two of R2, R3 and R4 are CH3.  
 
     
 11. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein each of W1, W2, and W3 is -CH2CH(CH3)-.  
 
     
 12. The compound of claim 1, wherein said compound is selected from:                      or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 13. The compound of claim 12, wherein said compound is Compound 2, or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 14. The compound of claim 12, wherein said compound is selected from Compounds 17 and 18, or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 15. The compound of claim 12, wherein said compound is selected from Compounds 3 to 7, 9 to 12 and 46, or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 16. The compound of claim 12, wherein said compound is a selected from Compounds 4 to 7, 10 and 46, or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 17. The compound of claim 12, wherein said compound is a compound selected from Compounds 3 and 60 to 76, or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 18. The compound of claim 12, wherein said compound is Compound 8, or a pharmaceutically acceptable salt or prodrug thereof.  
 
     
 19. A process for making a compound of any one of claims 1-18, comprising cultivation of a Micromonospora sp. strain, in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, isolation and purification of the compound, and chemical modification of the isolated compound.  
 
     
 20. A pharmaceutical composition comprising a compound of any one of claims 1 to 11, together with a pharmaceutically acceptable carrier.  
 
     
 21. A pharmaceutical composition comprising a compound of claim 12, together with a pharmaceutically acceptable carrier.  
 
     
 22. A pharmaceutical composition comprising a compound of claim 13, together with a pharmaceutically acceptable carrier.  
 
     
 23. A pharmaceutical composition comprising a compound of any one of claims 14-18, together with a pharmaceutically acceptable carrier.  
 
     
 24. Use of a compound of any one of claims 1-12 as an antitumor agent.  
 
     
 25. Use of a compound of claim 13 as an antitumor agent.  
 
     
 26. Use of a compound of any one of claims 14-17 as an antitumor agent.  
 
     
 27. Use of a compound of any one of claims 1-12 for the treatment of precancerous or cancerous conditions.  
 
     
 28. Use of a compound of claim 13 for the treatment of precancerous or cancerous conditions.  
 
     
 29. Use of a compound of any one of claims 14-17 for the treatment of precancerous or cancerous conditions.  
 
     
 30. Use of a compound of any one of claims 1-12, in the manufacture of a medicament for the treatment of precancerous or cancerous conditions.  
 
     
 31. Use of a compound of claim 13, in the manufacture of a medicament for the treatment of precancerous or cancerous conditions.  
 
     
 32. Use of a compound of any one of claims 14-17, in the manufacture of a medicament for the treatment of precancerous or cancerous conditions.  
 
     
 33. Use of a compound of any one of claims 1-18 as a peripheral benzodiazepine receptor (PBR) binding agent for the treatment of a condition involving PBR.  
 
     
 34. Use of a compound of any one of claims 1-17 as a 5-Lipooxygenase (5-LO) inhibitor for the treatment of a condition involving the 5-LO enzyme.  
 
   
 
 
 
 
 
 
 
 
